COMP <GO>
DBD vs RTX // EV/EBITDA & P/E VALUATION
Diebold Nixdorf Incorporated (NYSE) VS. RTX Corporation (NYSE) • 15-METRIC TALLY: DBD 4
— RTX 8
▲ EV/EBITDA & P/E VALUATION LEADER: DBD
LAST: $59.14 (+1.84%) • MKT CAP: $1.99B
valuation
10.6x
LAST: $199.40 (+1.82%) • MKT CAP: $269.08B
valuation
26.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DBD VS. RTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DBD | RTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.50% | 7.20% | +4.30 | DBD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 10.6x | 26.5x | -15.90 | DBD | /valuation <GO> |
| Free Cash Flow Yield | 15.14% | 2.95% | +12.19 | DBD | /fcf-yield <GO> |
| Operating Margin | 6.40% | 10.50% | -4.10 | RTX | /operating-margins <GO> |
| Net Profit Margin | 2.50% | 7.60% | -5.10 | RTX | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | 9.70% | -8.20 | RTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.33% | -1.33 | RTX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.79 | 2.73 | -0.94 | RTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | RTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.7 | 60.0 | -32.32 | RTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.5x | 37.2x | -17.70 | DBD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.99B | $269.08B | -$267.09B | RTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DBD REV | RTX REV | DBD GROSS % | RTX GROSS % | DBD FCF | RTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.81B | $88.60B | 25.3% | — | $300.7M | $7.94B |
| FY 2024 | $3.75B | $80.74B | 24.5% | — | $149.2M | $4.53B |
| FY 2023 | — | $68.92B | — | — | — | $4.78B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DBD // BETA —
RTX // BETA 0.92